Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 23.71% is 14% below its 5-year average of 27.49%, around the middle of its 5-year range (1.66%–46.23%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.86% below its 12-month average of 27.52%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 23.71%.
DEBT TO ASSETS RATIO
23.71%
DEBT TO ASSETS RATIO AVG TTM
27.52%
DEBT TO ASSETS RATIO AVG 3Y
31.87%
DEBT TO ASSETS RATIO AVG 5Y
27.49%
DEBT TO ASSETS RATIO AVG 10Y
37.44%
DEBT TO ASSETS RATIO AVG 15Y
22.89%
DEBT TO ASSETS RATIO AVG 20Y
19.66%
CURRENT VS TTM AVG
-13.86%
CURRENT VS 3Y AVG
-25.61%
CURRENT VS 5Y AVG
-13.77%
CURRENT VS 10Y AVG
-36.68%
CURRENT VS 15Y AVG
+3.58%
CURRENT VS 20Y AVG
+20.56%
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 595 covered companies
CURRENT VS SECTOR MEDIAN
+23605.91%
vs the sector median at left
Lexicon Pharmaceuticals, Inc.
Market Cap
$768.50M
Debt to Assets Ratio
23.71%
TTM Avg
27.52%
3Y Avg
31.87%
5Y Avg
27.49%
Market Cap
$769.43M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$753.89M
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$750.11M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$791.01M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$745.00M
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$742.59M
Debt to Assets Ratio
0.24%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lexicon Pharmaceuticals, Inc. (LXRX) | $768.50M | 23.71% | 27.52% | 31.87% | 27.49% |
| Mesa Laboratories, Inc. (MLAB)vs › | $769.43M | 0.24% | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $769.83M | 0.24% | N/A | N/A | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $753.89M | 0.03% | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $750.11M | 0.01% | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.01M | 0.02% | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $745.00M | 0.06% | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $793.88M | 0.48% | N/A | N/A | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $742.59M | 0.24% | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $808.81M | 0.01% | N/A | N/A | N/A |
Debt/Assets
23.7%
Debt/Equity
0.34
Current Ratio
13.37
Interest Coverage
-5.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 23.71% |
| 2026-03-31 | 21.47% |
| 2025-12-31 | 33.64% |
| 2025-09-30 | 31.54% |
| 2025-06-30 | 27.24% |
| 2025-03-31 | 35.70% |
| 2024-12-31 | 36.32% |
| 2024-09-30 | 32.97% |
| 2024-06-30 | 28.30% |
| 2024-03-31 | 25.46% |
| 2023-12-31 | 46.23% |
| 2023-09-30 | 38.34% |
| 2023-06-30 | 33.32% |
| 2023-03-31 | 34.16% |
| 2022-12-31 | 28.46% |
| 2022-09-30 | 15.98% |
| 2022-06-30 | 22.63% |
| 2022-03-31 | 18.74% |
| 2021-12-31 | 1.66% |
| 2021-09-30 | 8.24% |
| 2021-06-30 | 7.40% |
| 2021-03-31 | 7.45% |
| 2020-12-31 | 6.29% |
| 2020-09-30 | 11.67% |
| 2020-06-30 | 76.21% |
| 2020-03-31 | 66.17% |
| 2019-12-31 | 59.09% |
| 2019-09-30 | 55.14% |
| 2019-06-30 | 105.11% |
| 2019-03-31 | 94.78% |
| 2018-12-31 | 86.23% |
| 2018-09-30 | 78.97% |
| 2018-06-30 | 73.62% |
| 2018-03-31 | 63.44% |
| 2017-12-31 | 56.28% |
| 2017-09-30 | 30.39% |
| 2017-06-30 | 27.66% |
| 2017-03-31 | 25.49% |
| 2016-12-31 | 21.33% |
| 2016-09-30 | 19.70% |
| 2016-06-30 | 18.31% |
| 2016-03-31 | 16.78% |
| 2015-12-31 | 16.16% |
| 2015-09-30 | 27.17% |
| 2015-06-30 | 25.66% |
| 2015-03-31 | 24.11% |
| 2014-12-31 | 22.84% |
| 2014-09-30 | 10.99% |
| 2014-06-30 | 9.39% |
| 2014-03-31 | 8.81% |
| 2013-12-31 | 7.98% |
| 2013-09-30 | 7.44% |
| 2013-06-30 | 7.01% |
| 2013-03-31 | 6.64% |
| 2012-12-31 | 6.31% |
| 2012-09-30 | 6.66% |
| 2012-06-30 | 6.35% |
| 2012-03-31 | 6.09% |
| 2011-12-31 | 5.78% |
| 2011-09-30 | 8.56% |
| 2011-06-30 | 8.09% |
| 2011-03-31 | 8.21% |
| 2010-12-31 | 7.76% |
| 2010-09-30 | 7.75% |
| 2010-06-30 | 12.33% |
| 2010-03-31 | 15.83% |
| 2009-12-31 | 25.98% |
| 2009-09-30 | 30.23% |
| 2009-06-30 | 27.41% |
| 2009-03-31 | 18.38% |
| 2008-12-31 | 11.66% |
| 2008-09-30 | 10.83% |
| 2008-06-30 | 9.97% |
| 2008-03-31 | 9.26% |
| 2007-12-31 | 8.50% |
| 2007-09-30 | 8.35% |
| 2007-06-30 | 15.82% |
| 2007-03-31 | 19.11% |
| 2006-12-31 | 16.92% |
| 2006-09-30 | 22.00% |
| 2006-06-30 | 20.02% |
| 2006-03-31 | 18.08% |
| 2005-12-31 | 16.89% |
| 2005-09-30 | 17.76% |
| 2005-06-30 | 19.41% |
| 2005-03-31 | 19.83% |
| 2004-12-31 | 17.75% |
| 2004-09-30 | 17.57% |
| 2004-06-30 | 17.16% |
| 2004-03-31 | 21.43% |
| 2003-12-31 | 19.83% |
| 2003-09-30 | 1.91% |
| 2003-06-30 | 2.31% |
| 2003-03-31 | 2.20% |
| 2002-12-31 | 1.98% |
| 2002-09-30 | 0.00% |
